Search results for " Blood Glucose"

showing 10 items of 29 documents

The pancreatic beta-cell response to intravenous administration of glucose in elderly subjects.

1970

A study was made of the serum insulin level after the intravenous administration of glucose (0.33 gm/ kg) in two groups of normal subjects—18 in the 60–85 age bracket, and 16 in the 23–45 age bracket. All had a normal coefficient of glucose utilization and a normal blood glucose curve after intravenous administration of glucose. Serum insulin was assayed by the radio-immunological method, with use of an ion exchange resin. Blood samples were drawn at 2, 5, 10, 30, 45 and 60 minutes after the end of the glucose infusion. In the elderly subjects the maximal value was reached only after 5 minutes and the mean value was 39± 9 µU/ml (range, 27–50), whereas in the younger subjects the serum insul…

AdultBlood GlucoseGlucose utilizationmedicine.medical_specialtymedicine.medical_treatmentRadioimmunoassayStimulationGlucose infusionInternal medicineMedicineHumansInsulinPancreasAgedbusiness.industryInsulinMean valueAge FactorsGlucose Tolerance TestMiddle AgedPeripheralEndocrinologyGlucoseInjections IntravenousGeriatrics and GerontologyBeta cellbusinessNormal blood glucoseJournal of the American Geriatrics Society
researchProduct

Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Der…

2021

Abstract Aim Immune checkpoint inhibition (ICI) triggers immune-related adverse events (irAEs). The relevance of lipase elevation remains unclear. Patients and methods Skin cancer patients with newly detected serum lipase elevation (at least twofold upper normal limit) or newly diagnosed type I diabetes mellitus upon ICI therapy were retrospectively collected at 14 German skin cancer centres. Results We identified 68 patients with lipase elevation occurring after a median time of 19 (range 1–181) weeks on ICI, 15 (22%) thereof had symptoms consistent with pancreatitis. Forty-seven patients (73%) had other irAE, mainly colitis. Discontinuation (n = 24, 35%) or interruption (n = 26, 38%) of I…

AdultBlood GlucoseMale0301 basic medicineCancer Researchmedicine.medical_specialtySkin NeoplasmsTime FactorsMedizinGastroenterologyThyroiditisYoung Adult03 medical and health sciences0302 clinical medicinePredictive Value of TestsGermanyInternal medicineDiabetes mellitusmedicineHumansLipaseAdverse effectImmune Checkpoint InhibitorsMelanomaAgedRetrospective StudiesAged 80 and overType 1 diabetesbiologybusiness.industryDiabetes; Diabetes mellitus; Immune checkpoint inhibitors; Immune-related adverse events; Ipilimumab; Lipase; Nivolumab; Pancreatitis; PD-1 inhibitor; Pembrolizumab; Adult; Aged; Aged 80 and over; Biomarkers; Blood Glucose; Diabetes Mellitus Type 1; Exocrine Pancreatic Insufficiency; Female; Germany; Humans; Immune Checkpoint Inhibitors; Lipase; Male; Melanoma; Middle Aged; Pancreatitis; Predictive Value of Tests; Retrospective Studies; Skin Neoplasms; Time Factors; Treatment Outcome; Up-Regulation; Young AdultLipaseMiddle Agedmedicine.diseaseUp-RegulationKetoacidosisDiabetes Mellitus Type 1Treatment Outcome030104 developmental biologyPancreatitisOncology030220 oncology & carcinogenesisbiology.proteinPancreatitisExocrine Pancreatic InsufficiencyFemaleSkin cancerbusinessBiomarkersEuropean Journal of Cancer
researchProduct

Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study

2021

Abstract Background The European Society of Cardiology (ESC) recently defined cardiovascular risk classes for subjects with diabetes. Aim of this study was to explore the distribution of subjects with type 2 diabetes (T2D) by cardiovascular risk groups according to the ESC classification and to describe the quality indicators of care, with particular regard to cardiovascular risk factors. Methods The study is based on data extracted from electronic medical records of patients treated at the 258 Italian diabetes centers participating in the AMD Annals initiative. Patients with T2D were stratified by cardiovascular risk. General descriptive indicators, measures of intermediate outcomes, inten…

AdultBlood GlucoseMalelcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_specialtyTime FactorsEndocrinology Diabetes and MetabolismType 2 diabetesIncretinsRisk AssessmentDiabetes mellitusInternal medicinemedicineElectronic Health RecordsHumansHypoglycemic AgentsMedical prescriptionSodium-Glucose Transporter 2 InhibitorsOriginal InvestigationAgedQuality Indicators Health CareRetrospective StudiesAngiologyCardiovascular risk Humans Hypoglycemic Agents Incretins Italy Male Middle Aged Retrospective Studies Risk Assessment Sodium-Glucose Transporter 2 Inhibitors Time Factors Treatment Outcome Quality Indicators Health Care Quality of care Type 2 diabetes Adult Aged Aged 80 and over Biomarkers Blood Glucose Cardiovascular Diseases Diabetes Mellitus Type 2 Dipeptidyl-Peptidase IV Inhibitors Heart Disease Risk Factors Female Electronic Health RecordsAged 80 and overDipeptidyl-Peptidase IV Inhibitorsbusiness.industryMedical recordQuality of careType 2 diabetesRetrospective cohort studyMiddle AgedCardiovascular riskmedicine.diseaseTreatment OutcomeDiabetes Mellitus Type 2ItalyCardiovascular DiseasesHeart Disease Risk Factorslcsh:RC666-701AlbuminuriaFemaleObservational studymedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkersCardiovascular Diabetology
researchProduct

Visceral adiposity index and DHEAS are useful markers of diabetes risk in women with polycystic ovary syndrome

2014

ObjectiveOn the basis of the known diabetes risk in polycystic ovary syndrome (PCOS), recent guidelines of the Endocrine Society recommend the use of an oral glucose tolerance test (OGTT) to screen for impaired glucose tolerance (IGT) and type 2 diabetes (T2DM) in all women with PCOS. However, given the high prevalence of PCOS, OGTT would have a high cost–benefit ratio. In this study, we identified, through a receiver operating characteristic analysis, simple predictive markers of the composite endpoint (impaired fasting glucose (IFG) or IGT or IFG+IGT or T2DM) in women with PCOS according to the Rotterdam criteria.DesignWe conducted a cross-sectional study of 241 women with PCOS in a unive…

AdultBlood Glucosemedicine.medical_specialtyDiabetes riskWaistendocrine system diseasesAdolescentEndocrinology Diabetes and MetabolismType 2 diabetesIntra-Abdominal FatSettore MED/13 - EndocrinologiaImpaired glucose toleranceYoung AdultInsulin resistanceEndocrinologyAdiposity; Adolescent; Adult; Biological Markers; Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus Type 2; Female; Humans; Intra-Abdominal Fat; Polycystic Ovary Syndrome; Risk Factors; Young Adult; Endocrinology; Endocrinology Diabetes and Metabolism; Medicine (all)Risk FactorsInternal medicineDiabetes mellitusmedicineHumansAdiposityCross-Sectional Studiebusiness.industryRisk FactorMedicine (all)nutritional and metabolic diseasesGeneral MedicineImpaired fasting glucosemedicine.diseasePolycystic ovaryCross-Sectional StudiesEndocrinologyDiabetes Mellitus Type 2Biological MarkerFemalebusinessBiomarkersHumanPolycystic Ovary Syndrome
researchProduct

Gender differences on oxidative stress markers and complement component C3 plasma values after an oral unsaturated fat load test

2020

Abstract Objective Post-prandial lipaemia (PL), oxidative stress (OS), and complement component C3 (C3) values are related to the atherosclerosis process. The post-prandial response of C3 after an oral fat load test (OFLT) using unsaturated fat is poorly addressed. The aim of this study was to analyze and compare the post-prandial response of OS markers and C3 values in men and women after an OFLT using unsaturated fat. Methods The study included a total of 22 healthy subjects with normal lipids and normal blood glucose (11 men and 11 pre-menopausal women). An oral unsaturated fat load test (OFLT: 50 g fat per m2 body surface) was performed using a commercial liquid preparation of long chai…

AdultMalemedicine.medical_specialty030209 endocrinology & metabolismmedicine.disease_cause03 medical and health scienceschemistry.chemical_compoundSex Factors0302 clinical medicineInternal medicinemedicineHumansPharmacology (medical)TriglyceridesFasting stateGeneral Environmental Science030219 obstetrics & reproductive medicineGlutathione Disulfidebusiness.industryUnsaturated fatHealthy subjectsGeneral EngineeringComplement C3FastingGlutathioneMiddle AgedPostprandial PeriodGlutathioneLipidsFats UnsaturatedOxidized GlutathioneOxidative StressEndocrinologychemistryGeneral Earth and Planetary SciencesFemaleCardiology and Cardiovascular MedicineNormal blood glucosebusinessLong chainBiomarkersOxidative stressClínica e Investigación en Arteriosclerosis (English Edition)
researchProduct

Evaluation of B-cell secretion and peripheral insulin resistance during pregnancy and after delivery in gestational diabetes mellitus with obesity

1988

Nine pregnant women with gestational diabetes mellitus (GDM) were studied. Six normal pregnant women and six normal nonpregnant women were evaluated as control groups. All the women underwent oral glucose tolerance test and glucose clamp during the third trimester of pregnancy and two months after delivery. During OGTT, glucose, C-peptide and insulin plasma levels were determined. C-peptide and insulin values in the late phase of OGTT were higher during pregnancy than after delivery in both groups. In gestational diabetic women, the M-value in the second steady-state during glucose clamp was lower than in controls, both during pregnancy and after delivery. Nevertheless, in both groups the M…

Blood GlucoseAdultmedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPregnancy in DiabeticsObesity; Glucose Tolerance Test; Reference Values; Humans; Diabetes Mellitus; Islets of Langerhans; Insulin; Blood Glucose; Pregnancy; Puerperal Disorders; Adult; Insulin Resistance; Female; Pregnancy in DiabeticsIslets of LangerhansEndocrinologyInsulin resistanceReference ValuesPregnancyDiabetes mellitusInternal medicineInternal MedicinemedicineDiabetes MellitusHumansInsulinObesityPregnancyGlucose tolerance testSettore MED/12 - Gastroenterologiamedicine.diagnostic_testbusiness.industryInsulinGeneral MedicinePuerperal DisordersGlucose clamp techniqueGlucose Tolerance Testmedicine.diseaseGestational diabetesEndocrinologyGestationFemaleInsulin Resistancebusiness
researchProduct

Filling the gap between Guidelines and Real World in the cardiovascular approach to the diabetic patients: the need for a call to action

2020

Blood GlucoseAmerican diabetes associationmedicine.medical_specialtybusiness.industryLow density lipoprotein cholesterolCardiovascular outcome trials Cardiovascular prevention Cardiovascular risk Diabetes mellitus type 2 Glucose-lowering drugs Therapeutical targets Blood Glucose Humans Hypoglycemic Agents Cardiovascular Diseases Diabetes Mellitus Type 2 Sodium-Glucose Transporter 2 InhibitorsCall to actionProprotein Convertase Subtilisin/Kexin 9Diabetes Mellitus Type 2Cardiovascular preventionCardiovascular DiseasesHumansHypoglycemic AgentsMedicineCardiology and Cardiovascular MedicinebusinessIntensive care medicineSodium-Glucose Transporter 2 InhibitorsGlycated haemoglobin
researchProduct

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

2015

BACKGROUND: Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon-like peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously. METHODS: We conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 30 or a BMI of at least 27 if they had treated or untreated dyslipidemia or hypertension. We randomly assigned patients in a 2:1 ratio to receive on…

Blood GlucoseCounselingMaleType 2 diabeteslaw.inventionBody Mass IndexRandomized controlled trialWeight losslawGlucagon-Like Peptide 1Weight managementSubcutaneousMedicine (all)ReducingNauseaGeneral MedicineMiddle AgedCombined Modality Therapy3. Good healthFemaletype 2 diabetesmedicine.symptomHumanmedicine.drugAdultDiarrheamedicine.medical_specialtyDiet ReducingInjections SubcutaneousInjections SubcutaneouPlaceboInjectionsDouble-Blind MethodInternal medicineWeight LossmedicineHumansHypoglycemic AgentsObesityExerciseHypoglycemic AgentLiraglutidebusiness.industryLiraglutidemedicine.diseaseWeight LoDietEndocrinologybusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionBody mass index[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyDyslipidemiaAdult; Blood Glucose; Body Mass Index; Combined Modality Therapy; Counseling; Diarrhea; Diet Reducing; Double-Blind Method; Exercise; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Nausea; Obesity; Weight Loss; Medicine (all)The New England journal of medicine
researchProduct

Influence of dietary fat and carbohydrates proportions on plasma lipids, glucose control and low-grade inflammation in patients with type 2 diabetes—…

2015

Purpose: The optimal macronutrient composition of the diet for the management of type 2 diabetes is debated, particularly with regard to the ideal proportion of fat and carbohydrates. The aim of the study was to explore the association of different proportions of fat and carbohydrates of the diet—within the ranges recommended by different guidelines—with metabolic risk factors. Methods: We studied 1785 people with type 2 diabetes, aged 50–75, enrolled in the TOSCA.IT Study. Dietary habits were assessed using a validated food-frequency questionnaire (EPIC). Anthropometry, fasting lipids, HbA1c and C-reactive protein (CRP) were measured. Results: Increasing fat intake from <25 to ≥35 % is …

Blood GlucoseDietary FiberMale0301 basic medicineGlycated Hemoglobin AGlucose controlMedicine (miscellaneous)Type 2 diabetesSettore MED/13 - Endocrinologia0302 clinical medicineRisk FactorsSurveys and QuestionnairesDietary fatfat plsam lipids low-grade inflammationNutritional guidelinesNutrition and DieteticsbiologyType 2 diabetesMiddle AgedHDL-cholesterolCholesterolC-Reactive ProteinCarbohydrates diet fat Glucose control HDL-cholesterol Nutritional guidelines Triglycerides Type 2 diabetesCarbohydrates; Diet; Fat; Glucose control; HDL-cholesterol; Nutritional guidelines; Triglycerides; Type 2 diabetesFemaleDietary ProteinsType 2Dietary Carbohydratesmedicine.medical_specialtyHDLCarbohydrates030209 endocrinology & metabolismLDL03 medical and health sciencesInternal medicineGlucose controlPlasma lipidsDiabetes MellitusDietary CarbohydratesmedicineHumansIn patientCarbohydrates; Diet; Fat; Glucose control; HDL-cholesterol; Nutritional guidelines; Triglycerides; Type 2 diabetes; Medicine (miscellaneous); Nutrition and DieteticsTriglyceridesAgedGlycated HemoglobinInflammation030109 nutrition & dieteticsbusiness.industryCholesterol HDLC-reactive proteinCholesterol LDLAnthropometrymedicine.diseaseDietary FatsDietEndocrinologyDiabetes Mellitus Type 2Fatbiology.proteinDiet · Carbohydrates · Fat · Glucose control · HDL-cholesterol · Triglycerides · Type 2 diabetes · Nutritional guidelinesCarbohydrates; Diet; Fat; Glucose control; HDL-cholesterol; Nutritional guidelines; Triglycerides; Type 2 diabetes; Aged; Blood Glucose; C-Reactive Protein; Cholesterol HDL; Cholesterol LDL; Diabetes Mellitus Type 2; Dietary Carbohydrates; Dietary Fats; Dietary Fiber; Dietary Proteins; Energy Intake; Female; Glycated Hemoglobin A; Humans; Inflammation; Male; Middle Aged; Risk Factors; Surveys and Questionnaires; TriglyceridesEnergy IntakebusinessEuropean Journal of Nutrition
researchProduct

Glycemic Variability, Glycated Hemoglobin, and Cardiovascular Complications: Still a Dilemma in Clinical Practice

2021

Blood GlucoseGlycated Hemoglobinmedicine.medical_specialtybusiness.industryPharmacology toxicologyGeneral MedicineGlycated Hemoglobin A Humans Blood Glucose Diabetic AngiopathiesRheumatologyDilemmaClinical Practicechemistry.chemical_compoundchemistryInternal medicinemedicineHumansPharmacology (medical)Glycated hemoglobinbusinessIntensive care medicineDiabetic AngiopathiesGlycemic
researchProduct